Track CEL-SCI Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

CEL-SCI Corporation CVM · Stock Open CEL-SCI Corporation in new tab

1.28 USD
EPS
-1.69
P/B
2.10
ROE
-252.53
Beta
0.62
Target Price
12.50 USD
Loading chart...
Key Metrics
Earnings dateDec. 23, 2026
EPS-1.69
Book Value0.62
Price to Book2.10
Debt/Equity72.10
% Insiders3.715%
Estimates
Forward P/E-0.21
Forward EPS-6.38
Target Mean Price12.50

DCF valuation

Model fair value for CEL-SCI Corporation (CVM)
Result
Sign in to run the valuation for CVM.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
2 analysts · consensus None · mean target 12.50 USD (low 10.00, high 15.00) · as of 12 Nov 2026
Low 10.00
Mean 12.50
High 15.00
Price 1.28
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

CEL-SCI Corporation Logo CEL-SCI Corporation Analysis (CVM)

United States Health Care Official Website Stock

Is CEL-SCI Corporation a good investment? CEL-SCI Corporation (CVM) is currently trading at 1.28 USD. Market analysts have a consensus price target of 12.50 USD. This suggests a potential upside from current levels.

Earnings Schedule: CEL-SCI Corporation is expected to release its next earnings report on Dec. 23, 2026. The market consensus estimate for Forward EPS is -6.38.

Investor FAQ

Does CEL-SCI Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is CEL-SCI Corporation?

CEL-SCI Corporation is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Dec. 23, 2026. The company currently has a trailing EPS of -1.69.

Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

Exchange Ticker
ASE (United States) CVM
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸1996
0.01 USD
Aug. 28, 1996 0.0083
Stock Splits
Split Date Split Ratio to 1
May 1, 1995 1:10
Sept. 25, 2013 1:10
June 15, 2017 1:25
May 20, 2025 0.03
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion